{{Distinguish|Prazepine}}
{{Drugbox
| Watchedfields = changed
| verifiedrevid = 464213409
| IUPAC_name = 7-Chloro-1-(cyclopropylmethyl)-5-phenyl-1,3-dihydro-2''H''-1,4-benzodiazepin-2-one
| image = Prazepam.svg
| width = 180
| image2 = Prazepam3d.png
| width2 = 140

<!--Clinical data-->
| tradename = 
| Drugs.com = {{drugs.com|CONS|prazepam}}
| MedlinePlus = a601036
| pregnancy_category =
| legal_CA = Schedule IV
| legal_DE = Rx-only/Anlage III
| legal_US = Schedule IV
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =
| metabolism = [[Liver|Hepatic]]
| elimination_half-life = 36–200 hours
| excretion = [[Kidney|Renal]]

<!--Identifiers-->
| IUPHAR_ligand = 7275
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 2955-38-6
| ATC_prefix = N05
| ATC_suffix = BA11
| ATC_supplemental = 
| PubChem = 4890
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01588
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4721
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = Q30VCC064M
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00470
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 969

<!--Chemical data-->
| C=19 | H=17 | Cl=1 | N=2 | O=1
| molecular_weight = 324.8 g/mol
| smiles = Clc4cc\1c(N(C(=O)C/N=C/1c2ccccc2)CC3CC3)cc4
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C19H17ClN2O/c20-15-8-9-17-16(10-15)19(14-4-2-1-3-5-14)21-11-18(23)22(17)12-13-6-7-13/h1-5,8-10,13H,6-7,11-12H2
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = MWQCHHACWWAQLJ-UHFFFAOYSA-N
| synonyms = <small>9-chloro-2-(cyclopropylmethyl)-6-phenyl-2,5-diazabicyclo[5.4.0]undeca-5,8,10,12-tetraen- 3-one</small>
}}

'''Prazepam''' is a [[benzodiazepine]] [[Derivative (chemistry)|derivative]] [[drug]] developed by Warner-Lambert in the 1960s.<ref>US Patent 3192199 – Process for the production of I-CYCLO- ALKYL derivatives of I,X-BENZODIAZEPINE</ref> It possesses [[anxiolytic]], [[anticonvulsant]], [[sedative]] and [[skeletal muscle relaxant]] properties.<ref>{{cite journal |vauthors=Shader RI, Greenblatt DJ |title=Benzodiazepines: some aspects of their clinical pharmacology |journal=Ciba Found. Symp. |volume=1979 |issue=74 |pages=141–55 |year=1979 |pmid=45081 |doi= |url=}}</ref> Prazepam is a [[prodrug]] for [[desmethyldiazepam]] which is responsible for the therapeutic effects of prazepam.<ref>{{cite journal |vauthors=Jacqmin P, Ansseau M |title=Comparison of sublingual and oral prazepam in normal subjects. II. Pharmacokinetic and pharmacodynamic data |journal=Neuropsychobiology |volume=19 |issue=4 |pages=186–91 |year=1988 |pmid=2854609 |doi= 10.1159/000118458|url=}}</ref>

== Indications ==
Prazepam is indicated for the short-term treatment of [[anxiety]]. After short-term therapy, the dose is usually gradually tapered-off to reduce or avoid any [[Drug withdrawal|withdrawal]] or [[rebound effects]].<ref>{{cite journal  |vauthors=Rickels K, Sablosky L, Silverman H, etal |title=Prazepam in anxiety: a controlled clinical trial |journal=Compr Psychiatry |volume=18 |issue=3 |pages=239–49 |year=1977 |pmid=858240 |doi= 10.1016/0010-440X(77)90018-9|url=http://linkinghub.elsevier.com/retrieve/pii/0010-440X(77)90018-9}}</ref><ref>{{cite journal |vauthors=Ansseau M, Von Frenckell R |title=(title in French) |trans_title=Value of prazepam drops in the brief treatment of anxiety disorders |language=French |journal=Encephale |volume=17 |issue=4 |pages=291–294 |year=1991 |pmid=1959497 |doi= |url=}}</ref> [[Desmethyldiazepam]], an [[active metabolite]], has a very long half-life of 29 to 224 hours, which contributes to the therapeutic effects of prazepam.<ref>{{cite journal |vauthors=Breimer DD, Jochemsen R, von Albert HH |title=Pharmacokinetics of benzodiazepines. Short-acting versus long-acting |journal=Arzneimittelforschung |volume=30 |issue=5a |pages=875–81 |year=1980 |pmid=6106488 |doi= |url=}}</ref><ref>{{cite journal |vauthors=Allen MD, Greenblatt DJ, Harmatz JS, Shader RI |title=Desmethyldiazepam kinetics in the elderly after oral prazepam |journal=Clin. Pharmacol. Ther. |volume=28 |issue=2 |pages=196–202 |date=August 1980 |pmid=6772370 |doi= 10.1038/clpt.1980.150|url=}}</ref>

== Side effects ==
Side effects of prazepam are less profound than with other [[benzodiazepines]].<ref>{{cite journal |vauthors=Greenblatt DJ, Harmatz JS, Dorsey C, Shader RI |title=Comparative single-dose kinetics and dynamics of lorazepam, alprazolam, prazepam, and placebo |journal=Clin. Pharmacol. Ther. |volume=44 |issue=3 |pages=326–34 |date=September 1988 |pmid=3138056 |doi= 10.1038/clpt.1988.158|url=}}</ref> Excessive [[drowsiness]] and with longer-term use, [[drug dependence]], are the most common side effects of prazepam.<ref>{{cite journal  |vauthors=Danion JM, Brion S, Escande M, etal |title=(title in French) |trans_title=Treatment of anxiety with prazepam, 40 mg. A controlled study versus lorazepam |language=French |journal=Encephale |volume=10 |issue=3 |pages=135–138 |year=1984 |pmid=6389091 }}</ref><ref>{{cite journal |vauthors=Dièye AM, Sy B, Diarra M, Faye B |title=(title in French) |trans_title=Prescription and use of benzodiazepins in Saint-Louis in Senegal: patient survey |language=French |journal=Ann Pharm Fr |volume=62 |issue=2 |pages=133–137 |date=March 2004 |pmid=15107731 |doi= |url=http://www.masson.fr/masson/MDOI-APF-03-2004-62-2-0003-4509-101019-ART9}}</ref> Side effects such as [[fatigue (medical)|fatigue]] or "feeling spacey" can also occur but less commonly than with other benzodiazepines. Other side effects include feebleness, clumsiness or [[lethargic]], clouded thinking and mental slowness.<ref>{{cite journal |vauthors=Shader RI, Pary RJ, Harmatz JS, Allison S, Locniskar A, Greenblatt DJ |title=Plasma concentrations and clinical effects after single oral doses of prazepam, clorazepate, and diazepam |journal=J Clin Psychiatry |volume=45 |issue=10 |pages=411–3 |date=October 1984 |pmid=6148339 |doi= |url=}}</ref><ref>{{cite journal |vauthors=Ansseau M, von Frenckell R, Jacqmin P |title=Comparison of sublingual and oral prazepam in normal subjects. I. Clinical data |journal=Neuropsychobiology |volume=18 |issue=2 |pages=77–82 |year=1987 |pmid=3330182 |doi= 10.1159/000118397|url=}}</ref><ref>{{cite journal |vauthors=Chabannes JP, Lemoine P |title=(title in French) |trans_title=Prazepam drops versus 10 mg prazepam tablets in anxious patients in ambulatory care |language=French |journal=Therapie |volume=45 |issue=6 |pages=467–470 |year=1990 |pmid=2080484 |doi= |url=}}</ref>

== Tolerance, dependence and withdrawal ==
{{See also|Benzodiazepine withdrawal syndrome}}
[[Drug tolerance|Tolerance]] and [[drug dependence|dependence]] can develop with long-term use of prazepam, and upon cessation or reduction in dosage, then a [[benzodiazepine withdrawal syndrome]] may occur with symptoms such as [[tremulousness]], [[dysphoria]], [[psychomotor agitation]], [[tachycardia]] and [[sweating]]. In severe cases, [[hallucinations]], [[psychosis]] and [[seizures]] can occur. [[Drug withdrawal|Withdrawal]]-related psychosis is generally unresponsive to antipsychotic mediations. The risk and severity of the withdrawal syndrome increases the higher the dose and the longer prazepam is taken for.<ref name="pmid6133535">{{cite journal |vauthors=Shader RI, Greenblatt DJ |title=The use of benzodiazepines in clinical practice |journal=Br J Clin Pharmacol |volume=Suppl 1 |issue= |pages=5S–9S |year=1981 |series=11 |pmid=6133535 |pmc=1401641 |doi= 10.1111/j.1365-2125.1981.tb01832.x}}</ref> Tolerance, dependence and withdrawal problems may be less severe than with other benzodiazepines, such as [[diazepam]].<ref>{{cite journal |author=Dorman T |title=A multi-centre comparison of prazepam and diazepam in the treatment of anxiety |journal=Pharmatherapeutica |volume=3 |issue=6 |pages=433–40 |year=1983 |pmid=6353434 |doi= |url=}}</ref> It may be because tolerance is slower to develop with prazepam than with other benzodiazepines.<ref>{{cite journal |vauthors=Saletu M, Saletu B, Grünberger J, Mader R, Karobath M |title=Clinical symptomatology and computer analyzed EEG before, during and after anxiolytic therapy of alcohol withdrawal patients |journal=Neuropsychobiology |volume=9 |issue=2–3 |pages=119–34 |year=1983 |pmid=6353268 |doi= 10.1159/000117949|url=}}</ref> Abrupt or over-rapid discontinuation of prazepam after long-term use, even at low dosage, may result in a [[protracted withdrawal syndrome]].<ref>{{cite journal |vauthors=Soyka M, Lehle R, Hippius H |title=(title in German) |trans_title=Exacerbation of an affective psychosis after terminating a decade of benzodiazepine treatment. Which therapeutic procedure is sensible? |language=German |journal=Nervenarzt |volume=65 |issue=9 |pages=628–32 |date=September 1994 |pmid=7991010 |doi= |url=}}</ref>

Benzodiazepines can induce serious problems of [[Substance dependence|addiction]], which is one of the main reasons for their use being restricted to short-term use. A survey in [[Senegal]] found that the majority of doctors believed that their training in this area was generally poor. Recommendations for national authorities to take urgent action regarding the rational use of benzodiazepines.<ref>{{cite journal |vauthors=Dièye AM, Sylla M, Ndiaye A, Ndiaye M, Sy GY, Faye B |title=Benzodiazepines prescription in Dakar: a study about prescribing habits and knowledge in general practitioners, neurologists and psychiatrists |journal=Fundam Clin Pharmacol |volume=20 |issue=3 |pages=235–8 |date=June 2006 |pmid=16671957 |doi=10.1111/j.1472-8206.2006.00400.x |url=http://www3.interscience.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0767-3981&date=2006&volume=20&issue=3&spage=235}}</ref> Another study in [[Dakar]] found that almost one-fifth of doctors ignored prescription guidelines regarding short-term use of benzodiazepines, and almost three-quarters of doctors regarded their training and knowledge of benzodiazepines to be inadequate. More training regarding benzodiazepines has been recommended for doctors.<ref>{{cite journal  |vauthors=Dièye AM, Sy AN, Sy GY, etal |title=(title in French) |trans_title=Prescription of benzodiazepines by general practitioners in the private sector of Dakar: survey on knowledge and attitudes |language=French |journal=Therapie |volume=62 |issue=2 |pages=163–168 |year=2007 |pmid=17582318 |doi=10.2515/therapie:2007018 |url=http://publications.edpsciences.org/10.2515/therapie:2007018}}</ref>

== Contraindications and special caution ==
Benzodiazepines require special precaution if used in the elderly, during pregnancy, in children, alcohol or drug-dependent individuals and individuals with [[comorbid]] [[psychiatric disorders]].<ref>{{cite journal  | last1 = Authier | first1 = N. | last2 = Balayssac | first2 = D. | last3 = Sautereau | first3 = M. | last4 = Zangarelli | first4 = A. | last5 = Courty | first5 = P. | last6 = Somogyi | first6 = AA. | last7 = Vennat | first7 = B. | last8 = Llorca | first8 = PM. | last9 = Eschalier | first9 = A. | title = Benzodiazepine dependence: focus on withdrawal syndrome. | journal = Ann Pharm Fr | volume = 67 | issue = 6 | pages = 408–13 |date=Nov 2009 | doi = 10.1016/j.pharma.2009.07.001 | pmid = 19900604 }}</ref>

== Mechanism of action ==
Prazepam exerts its therapeutic effects primarily via modulating the [[benzodiazepine receptor]] which in turn enhances [[GABA]] function in the brain.<ref name="pmid6114911">{{cite journal |author=Quast U |title=(title in German) |trans_title=Molecular mechanism of action of benzodiazepines |language=German |journal=Fortschr. Med. |volume=99 |issue=20 |pages=788–94 |date=May 1981 |pmid=6114911 |doi= |url=}}</ref> Prazepam like other benzodiazepines has [[anticonvulsant]] properties, but its anticonvulsant properties are not as potent as other benzodiazepines when tested in animal studies.<ref>{{cite journal |vauthors=De Sarro G, Gitto R, Rizzo M, Zappia M, De Sarro A |title=1,4-Benzodiazepine derivatives as anticonvulsant agents in DBA/2 mice |journal=Gen. Pharmacol. |volume=27 |issue=6 |pages=935–41 |date=September 1996 |pmid=8909973 |doi= 10.1016/0306-3623(95)02147-7|url=http://linkinghub.elsevier.com/retrieve/pii/0306362395021477}}</ref><ref>{{cite journal |vauthors=De Sarro G, Chimirri A, Zappala M, Guisti P, Lipartiti M, De Sarro A |title=Azirino&#91;1, 2-d&#93;&#91;1, 4&#93;benzodiazepine derivatives and related 1,4-benzodiazepines as anticonvulsant agents in DBA/2 mice |journal=Gen. Pharmacol. |volume=27 |issue=7 |pages=1155–1162 |date=October 1996 |pmid=8981061 |doi= 10.1016/S0306-3623(96)00049-3|url=http://linkinghub.elsevier.com/retrieve/pii/S0306362396000493}}</ref><ref>{{cite journal |vauthors=De Sarro G, Chimirri A, McKernan R, Quirk K, Giusti P, De Sarro A |title=Anticonvulsant activity of azirino&#91;1,2-d&#93;&#91;1,4&#93;benzodiazepines and related 1,4-benzodiazepines in mice |journal=Pharmacol. Biochem. Behav. |volume=58 |issue=1 |pages=281–289 |date=September 1997 |pmid=9264104 |doi= 10.1016/S0091-3057(96)00565-5|url=http://linkinghub.elsevier.com/retrieve/pii/S0091-3057(96)00565-5}}</ref><ref>{{cite journal |vauthors=Fukinaga M, Ishizawa K, Kamei C |title=Anticonvulsant properties of 1,4-benzodiazepine derivatives in amygdaloid-kindled seizures and their chemical structure-related anticonvulsant action |journal=Pharmacology |volume=57 |issue=5 |pages=233–241 |date=November 1998 |pmid=9742288 |doi= 10.1159/000028247|url=http://content.karger.com/produktedb/produkte.asp?typ=fulltext&file=pha57233}}</ref>

== Pharmacokinetics ==
Prazepam is metabolised into descyclopropylmethylprazepam (also known as [[desmethyldiazepam]]) and 3-hydroxyprazepam which is further metabolised into [[oxazepam]].<ref>{{cite journal |vauthors=Viau JP, Epps JE, Di Carlo J |title=Prazepam metabolism after chronic administration to humans |journal=Xenobiotica |volume=3 |issue=9 |pages=581–587 |date=September 1973 |pmid=4763144 |doi=10.3109/00498257309151546 |url=http://www.informapharmascience.com/doi/abs/10.3109/00498257309151546}}</ref><ref>{{cite journal |vauthors=Valavani P, Atta-Politou J, Panderi I |title=Development and validation of a liquid chromatographic/electrospray ionization mass spectrometric method for the quantitation of prazepam and its main metabolites in human plasma |journal=J Mass Spectrom |volume=40 |issue=4 |pages=516–26 |date=April 2005 |pmid=15712230 |doi=10.1002/jms.824}}</ref><ref>{{cite journal |vauthors=Lu XL, Guengerich FP, Yang SK |title=Stereoselective metabolism of prazepam and halazepam by human liver microsomes |journal=Drug Metab. Dispos. |volume=19 |issue=3 |pages=637–642 |year=1991 |pmid=1680631 |doi= |url=http://dmd.aspetjournals.org/cgi/content/abstract/19/3/637}}</ref><ref>{{cite journal |vauthors=Greenblatt DJ, Shader RI |title=Prazepam, a precursor of desmethyldiazepam |journal=Lancet |volume=1 |issue=8066 |pages=720 |date=April 1978 |pmid=76260 |doi=10.1016/S0140-6736(78)90834-6 |url=}}</ref><ref>{{cite journal |vauthors=Nau H, Liddiard C, Jesdinsky D, Wittfoht W |title=Quantitative analysis of prazepam and its metabolites by electron capture gas chromatography and selected ion monitoring. Application to diaplacetal passage and fetal hepatic metabolism in early human pregnancy |journal=J. Chromatogr. |volume=146 |issue=2 |pages=227–239 |date=September 1978 |pmid=701422 |doi= 10.1016/S0378-4347(00)81889-7|url=}}</ref> Prazepam is a [[prodrug]] for descyclopropylmethylprazepam/desmethyldiazepam (also known as norprazepam or [[nordazepam]]) which is responsible for most of the therapeutic activity of prazepam rather than prazepam itself.<ref name="pmid6133535" /><ref name="pmid6114911" /><ref>{{cite journal |author=Kölle EU |title=(title in German) |trans_title=Pharmacokinetics of oral prazepam |language=German |journal=Fortschr. Med. |volume=99 |issue=22 |pages=874–879 |date=June 1981 |pmid=6790396 |doi= |url=}}</ref><ref>{{cite journal |vauthors=Ochs HR, Greenblatt DJ, Verburg-Ochs B, Locniskar A |title=Comparative single-dose kinetics of oxazolam, prazepam, and clorazepate: three precursors of desmethyldiazepam |journal=J Clin Pharmacol |volume=24 |issue=10 |pages=446–51 |date=October 1984 |pmid=6150943 |doi= 10.1002/j.1552-4604.1984.tb01817.x|url=http://jcp.sagepub.com/cgi/content/abstract/24/10/446}}</ref>

== Interactions ==
Prazepam may interact with [[cimetidine]].<ref>{{cite journal |vauthors=Ruffalo RL, Thompson JF, Segal J |title=Cimetidine-benzodiazepine drug interaction |journal=Am J Hosp Pharm |volume=38 |issue=9 |pages=1365–1366 |date=September 1981 |pmid=6116430 |doi= |url=}}</ref> [[Ethanol|Alcohol]] in combination with prazepam increases the adverse effects, particularly performance impairing side effects and [[drowsiness]].<ref>{{cite journal |vauthors=Girre C, Hirschhorn M, Bertaux L, Palombo S, Fournier PE |title=Comparison of performance of healthy volunteers given prazepam alone or combined with ethanol. Relation to drug plasma concentrations |journal=Int Clin Psychopharmacol |volume=6 |issue=4 |pages=227–238 |year=1991 |pmid=1816280 |doi= 10.1097/00004850-199100640-00004|url=}}</ref>

== Overdose ==
{{See also|Benzodiazepine overdose}}
The symptoms of an [[overdose]] of prazepam include [[sleepiness]], [[psychomotor agitation|agitation]] and [[ataxia]]. [[Hypotonia]] may also occur in severe cases. Overdoses in children typically result in more severe symptoms of overdose.<ref>{{cite journal |vauthors=Pulce C, Mollon P, Pham E, Frantz P, Descotes J |title=Acute poisonings with ethyle loflazepate, flunitrazepam, prazepam and triazolam in children |journal=Vet Hum Toxicol |volume=34 |issue=2 |pages=141–143 |date=April 1992 |pmid=1354907 }}</ref>

== Abuse potential ==
{{See also|Benzodiazepine drug misuse}}
Prazepam like other benzodiazepines has abuse potential and can be [[habit forming]]. However, its abuse potential may be lower than other benzodiazepines because it has a slow onset of action.<ref name="pmid6133535" /><ref>{{cite journal |vauthors=Hakuba A, Matysiakiewicz J |title=Uzalezniajace właściwości prazepamu |trans_title=The habit-forming effect of prazepam |language=Polish |journal=Psychiatr. Pol. |volume=20 |issue=3 |pages=232–234 |year=1986 |pmid=3797537 }}</ref>

== Toxicity ==
Animal studies have found prazepam taken during pregnancy results in delayed growth and causes reproductive abnormalities.<ref>{{cite journal |vauthors=Fox KA, Guerriero FJ |title=Effect of benzodiazepines on age of vaginal perforation and first estrus in mice |journal=Res. Commun. Chem. Pathol. Pharmacol. |volume=21 |issue=1 |pages=181–184 |date=July 1978 |pmid=28555 |doi= |url=}}</ref><ref>{{cite journal |vauthors=Guerriero FJ, Fox KA |title=Benzodiazepines and reproduction of swiss-webster mice |journal=Res. Commun. Chem. Pathol. Pharmacol. |volume=13 |issue=4 |pages=601–10 |date=April 1976 |pmid=4863 |doi= |url=}}</ref><ref>{{cite journal |vauthors=Guerriero FJ, Fox KA |title=Benzodiazepine-induced suppression of estrous cycles in C57BL/6J mice |journal=Res. Commun. Chem. Pathol. Pharmacol. |volume=11 |issue=1 |pages=155–158 |date=May 1975 |pmid=239442 |doi= |url=}}</ref>

== Trade names ==
Common [[trade names]] include Centrac, Centrax, Demetrin, Lysanxia, Mono Demetrin, Pozapam, Prasepine, Prazene, Reapam and Trepidan. Trade names vary depending on the country; [[Austria]]: Demetrin, [[Belgium]]: Lysanxia, [[France]]: Lysanxia, [[Germany]]: Demetrin; Mono Demetrin, [[Greece]]: Centrac, [[Ireland]]: Centrax, [[Italy]]: Prazene; Trepidan, [[Macedonia (country)|Macedonia]]: Demetrin, Prazepam, [[Netherlands]]: Reapam, [[Portugal]]: Demetrin, [[South Africa]]: Demetrin, [[Switzerland]]: Demetrin, [[Thailand]]: Pozapam; Prasepine.<ref>{{cite web| url= http://www.non-benzodiazepines.org.uk/benzodiazepine-names.html| title=Benzodiazepine Names| accessdate=2009-05-31| publisher=non-benzodiazepines.org.uk}}</ref>

== See also ==
* [[Benzodiazepine]]
* [[Benzodiazepine dependence]]
* [[Long-term effects of benzodiazepines]]

== References ==
{{Reflist|2}}

== External links ==
* [http://www.inchem.org/documents/pims/pharm/pim680.htm Inchem – Prazepam]

{{Benzodiazepines}}
{{Anxiolytics}}
{{GABAAR PAMs}}

[[Category:Benzodiazepines]]
[[Category:Lactams]]
[[Category:Chloroarenes]]
[[Category:GABAA receptor positive allosteric modulators]]